OCT devices hold promise

Article

Improved imagery could help physicians learn more about diseases and treatment response

New optical coherence tomography (OCT) devices are in development with the goal of expanding the utility of OCT in the clinic by providing better resolution, faster speed, and software to help clinicians better understand the nuances of diseases and how they respond to therapy. Dr Jay S. Duker looked at the past, present and future of the technology during the Retina Subspeciality Day at the annual meeting of the American Academy of Ophthalmology.

The first OCTs that became commercially available in 1996 were time-domain (TD) instruments. Those reached their pinnacle in 2002 when the Stratus OCT was introduced by Zeiss. That instrument, which had 10 μm axial resolution and obtained 400 axial scans per second, remained the state-of-the-art technology until recently.

Over the past decade, many new OCT instruments have become available that are all based on Fourier-domain detection. Spectral-domain (SD) OCT became commercially available in 2006 and swept-source OCT is being used in research but is not yet commercially available. SD-OCT is faster than TD-OCT and can obtain from 20000 to 52000 scans per second. It also has a broader band width that increases the axial resolution from 4 to 7 μm.

Recent Videos
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Sunita Radhakrishnan, MD, an associate at the Glaucoma Center of San Francisco, speaks at the annual Glaucoma 360 meeting about electrical neurostimulation.
3 experts are featured in this series.
3 experts are featured in this series.
© 2025 MJH Life Sciences

All rights reserved.